Myasthenia Gravis, Generalized Clinical Trials
9 recruiting trials for Myasthenia Gravis, Generalized. Eligibility criteria explained in plain English.
Recruiting Trials
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from...
Myasthenia Gravis Foundation of America Global MG Patient Registry
The goal of this observational study is to learn about the experiences of people living with Myasthenia Gravis (MG) in the United States. The main questions it aims to answer are:...
Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC...
Generalized Myasthenia Gravis (gMG) is a rare chronic autoimmune disorder causing muscle weakness and fatigue, primarily due to autoantibodies that disrupt neuromuscular junction...
Markers of Favorable Response to Complement Inhibitors Therapy
Myasthenia gravis is an autoimmune neurological disease caused by autoantibodies primarily directed against components of the postsynaptic membrane of the neuromuscular junction....
Markers of Favorable Response to FcRn Inhibitors(INFORM)
Myasthenia gravis is an autoimmune neurological disease caused by autoantibodies primarily directed against components of the postsynaptic membrane of the neuromuscular junction....
Predictors and Prognostic Factors of Myasthenia Gravis Outcome
This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG....
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
Randomized, double-blind, placebo-controlled, parallel-group study with optional open-label extension.
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
The primary objective of this phase III trial is to investigate if Rituximab can reduce patients' functional impairment caused by MG. The secondary objectives of this trial are to...